Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][41]. Core Views - The pharmaceutical sector has shown resilience, outperforming the overall market with a 1.40% increase, while the total A-share market declined by 1.17% [1][32]. - The ANGPTL3 target has gained significant interest from multinational pharmaceutical companies (MNCs) due to its unique mechanism of action, which is non-LDLR dependent, making it effective in patients with LDLR deficiencies [3][30]. - The report highlights the potential for ANGPTL3 therapies to significantly lower LDL-C levels, especially in high-risk populations such as HoFH patients, and suggests a diversified drug development landscape with various forms of ANGPTL3 inhibitors [3][16]. Market Performance - The overall A-share market saw a decline of 1.17%, with the Shanghai Composite Index down 0.81% and the ChiNext Index up 2.35%. The biotechnology sector's performance was notably strong, with chemical pharmaceuticals rising by 3.92% [1][32]. - The TTM price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology sector stands at 40.75x, compared to the overall A-share market's 19.80x [37][41]. Key Companies and Investment Recommendations - **Mindray Medical (300760.SZ)**: Rated "Outperform" with a projected net profit of 116.7 billion CNY for 2024 [4]. - **WuXi AppTec (603259.SH)**: Rated "Outperform" with a projected net profit of 93.5 billion CNY for 2024 [4]. - **Aier Eye Hospital (300015.SZ)**: Rated "Outperform" with a projected net profit of 35.6 billion CNY for 2024 [4]. - **New Industries (300832.SZ)**: Rated "Outperform" with a projected net profit of 18.3 billion CNY for 2024 [4]. - **Huitai Medical (688617.SH)**: Rated "Outperform" with a projected net profit of 6.7 billion CNY for 2024 [4]. - **Kaili Medical (300633.SZ)**: Rated "Outperform" with a projected net profit of 1.4 billion CNY for 2024 [4]. - **Aohua Endoscopy (688212.SH)**: Rated "Outperform" with a projected net profit of 0.2 billion CNY for 2024 [4]. - **Edding Biological (300685.SZ)**: Rated "Outperform" with a projected net profit of 2.5 billion CNY for 2024 [4]. - **Aibo Medical (688050.SH)**: Rated "Outperform" with a projected net profit of 3.9 billion CNY for 2024 [4]. - **Kingdom Medical (603882.SH)**: Rated "Outperform" with a projected net profit of -3.8 billion CNY for 2024 [4]. ANGPTL3 Development Landscape - The report emphasizes the growing interest in ANGPTL3 as a therapeutic target, with MNCs like Novartis, Lilly, Amgen, and AstraZeneca actively pursuing drug development in this area [3][16]. - ANGPTL3 therapies are expected to provide significant benefits in managing lipid levels, particularly in patients with mixed dyslipidemia and high triglycerides [30][31].

Core Insights - On September 10, 2025, Alibaba-W (09988), Pop Mart (09992), and SMIC (00981) were the top three companies by trading volume in the Hong Kong Stock Connect (southbound), with trading amounts of 10.902 billion, 3.420 billion, and 3.019 billion respectively [1] - In the Shenzhen-Hong Kong Stock Connect (southbound), Alibaba-W (09988), Tencent Holdings (00700), and Xiaomi Group-W (01810) led the trading volume, with amounts of 5.893 billion, 2.042 billion, and 1.720 billion respectively [1] Southbound Trading Activity - The top active companies in the Hong Kong Stock Connect (southbound) included: - Alibaba-W (09988) with a trading amount of 10.902 billion and a net buying amount of +2.426 billion - Pop Mart (09992) with a trading amount of 3.420 billion and a net selling amount of -1.298 billion - SMIC (00981) with a trading amount of 3.019 billion and a net buying amount of +0.119 billion [2] - The top active companies in the Shenzhen-Hong Kong Stock Connect (southbound) included: - Alibaba-W (09988) with a trading amount of 5.893 billion and a net buying amount of +2.086 billion - Tencent Holdings (00700) with a trading amount of 2.042 billion and a net selling amount of -0.094 billion - Xiaomi Group-W (01810) with a trading amount of 1.720 billion and a net selling amount of -0.0115 billion [2]

阿里巴巴-W(09988) 港股通成交榜( | 日期 | 相关 | 收盘价 | 涨跌幅 | 港股通 净买额(港 | | --- | --- | --- | --- | --- | | | | | | 元) ? | | 2025-09-10 | 持股明细 | 142.80 | 0.63% | 45.11亿 | | 2025-09-09 | 持股明细 | 141.90 | 3.35% | 42.34亿 | | 2025-09-08 | 持股明细 | 137.30 | 4.17% | 51.46 Z | | 2025-09-05 | 持股明细 | 131.80 | 1.54% | 21.44亿 | | 2025-09-04 | 持股明细 | 129.80 | -3.21% | 5.5037亿 | | 2025-09-03 | 持股明细 | | 134.10 -0.45% | 24.89亿 | | 2025-09-02 | 持股明细 | | 134.70 -1.75% | 34.43 Z | | 2025-09-01 | 措股明细 | 137.10 | 18.50% | 49.21亿 | | 2025-08-29 | ...

南向资金今日净买入75.66亿港元。其中阿里巴巴-W、哔哩哔哩-W、南方恒生科技净买入额位列前三， 分别获净买入45.11亿港元、3.62亿港元、1.78亿港元。净卖出方面，泡泡玛特、康方生物、小米集团-W 分别遭净卖出17.11亿港元、9亿港元、4.41亿港元。 (本文来自第一财经) ...

Core Viewpoint - The Hong Kong stock market experienced significant net inflows from northbound trading, with a total net buy of HKD 75.66 billion on September 10, 2023, indicating strong investor interest in certain stocks [1]. Group 1: Stock Performance - Alibaba-W (09988) received the highest net buy of HKD 45.11 billion, driven by the launch of its "Gaode Street Ranking" and a support plan for offline businesses [4]. - Bilibili-W (09626) saw a net buy of HKD 3.62 billion, with the announcement of its new game "Three Kingdoms Hundred Generals Card" expected to attract significant daily active users [5]. - Xiaomi Group-W (01810) faced a net sell of HKD 4.4 billion due to internal issues related to a senior employee's misconduct [7]. Group 2: Other Notable Stocks - Meituan-W (03690) and Semiconductor Manufacturing International Corporation (00981) also experienced notable trading activity, with net buys of HKD 1.77 billion and HKD 1.61 billion respectively [7][5]. - The overall trading volume for Alibaba-W was HKD 109.02 billion, with a net inflow of HKD 24.26 billion [2]. - Tencent (00700) had a net sell of HKD 710.9 million, reflecting a decline in investor confidence [7]. Group 3: Market Trends - Northbound trading from the Shanghai and Shenzhen stock exchanges contributed significantly to the overall market activity, with net buys of HKD 25.36 billion and HKD 50.3 billion respectively [1]. - The market is showing a trend of increased interest in technology and gaming stocks, as evidenced by the performance of Alibaba and Bilibili [4][5].

（文章来源：每日经济新闻） 每经AI快讯，9月10日，南向资金净买入75.66亿港元。其中，阿里巴巴-W、哔哩哔哩-W、南方恒生科 技净买入额位列前三，分别获净买入45.11亿港元、3.62亿港元、1.78亿港元；泡泡玛特、康方生物、小 米集团-W分别遭净卖出17.11亿港元、9亿港元、4.41亿港元。 ...

Core Viewpoint - 招银国际 maintains a "Buy" rating for 康方生物 (09926), citing positive overall survival (OS) trends from the HARMONi trial, which enhances confidence in its first-line indication potential [1] Group 1: Clinical Trial Results - Summit released the latest data from the HARMONi global clinical trial, evaluating the efficacy of AK112 combined with chemotherapy versus chemotherapy alone in second-line EGFR-TKI resistant NSCLC patients [2] - Chinese patients demonstrated superior progression-free survival (PFS) results, with a median PFS of 6.8 months for AK112 combined with chemotherapy compared to 4.4 months for chemotherapy alone (HR=0.52, p<0.001) [3] - In long-term follow-up, the PFS HR slightly worsened to 0.57, potentially due to increased data maturity in Western populations, with North American and European patients showing PFS HRs of 0.67 and 0.55 respectively [3] Group 2: Overall Survival Analysis - In the final OS analysis, the median OS for the AK112 combined chemotherapy group was 16.8 months compared to 14.0 months for the chemotherapy alone group, with an HR of 0.79 (95% CI: 0.62–1.01, p=0.0570) [4] - Long-term follow-up showed an improvement in OS HR to 0.78 (95% CI: 0.62–0.98) with a nominal p-value of 0.0332, indicating a positive trend despite the FDA's reliance on pre-specified analysis results [4] - North American patients exhibited strong OS results with an HR of 0.70, although the confidence interval was wide (0.38–1.30) [5]

Core Viewpoint - The report from CMB International maintains a "Buy" rating for Kangfang Biotech (09926), highlighting positive overall survival (OS) trends from the HARMONi trial, which enhances confidence in its first-line indication potential [1] Group 1: Clinical Trial Results - The HARMONi trial assessed the efficacy of AK112 combined with chemotherapy versus chemotherapy alone in second-line treatment for third-generation EGFR-TKI resistant NSCLC patients, showing that Western patients had inferior progression-free survival (PFS) risk ratios compared to Chinese patients [1] - In the primary PFS analysis (n=345, median follow-up of 22.3 months), the median PFS for AK112 combined with chemotherapy was 6.8 months compared to 4.4 months for chemotherapy alone (HR=0.52, p<0.001) [2] - In longer follow-up (median 29.7 months), the PFS HR slightly worsened to 0.57, attributed to increased data maturity in Western populations, with North American and European patients showing PFS HR of 0.67 and Chinese patients at 0.55 [2] Group 2: Overall Survival Analysis - In the final OS analysis (n=438, overall median follow-up of 29.7 months), the median OS for the AK112 combined group was 16.8 months versus 14.0 months for the chemotherapy group, with an HR of 0.79 (95% CI: 0.62–1.01, p=0.0570), indicating an overall positive OS trend [3] - In non-predefined longer follow-up (32.7 months), the OS HR improved to 0.78 (95% CI: 0.62–0.98) for the Western patient cohort, with a nominal p-value of 0.0332, emphasizing the importance of mature long-term OS data for evaluating efficacy in Western patients [3] - North American patients showed strong OS results with an HR of 0.70, despite a wide confidence interval (0.38–1.30), while European patients had limited sample size and follow-up time [4]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][41]. Core Views - The pharmaceutical sector has shown resilience, outperforming the overall market with a 1.40% increase, while the total A-share market declined by 1.17% [1][32]. - ANGPTL3 has gained significant interest from multinational pharmaceutical companies (MNCs) due to its unique mechanism of action, which is non-LDLR dependent, making it effective in patients with LDLR deficiencies [3][30]. - The report highlights the diverse drug forms targeting ANGPTL3, with MNCs like Novartis, Lilly, Amgen, and AstraZeneca actively investing in this area, indicating a potential for multi-target and multi-drug combinations in the future [3][16]. Summary by Sections Market Performance - The overall A-share market fell by 1.17%, with the Shanghai and Shenzhen 300 index down by 0.81%. The biotechnology sector, however, rose by 1.40%, indicating strong performance relative to the broader market [1][32]. - Specific segments within the pharmaceutical sector showed varied performance, with chemical pharmaceuticals up by 3.92% and medical services up by 1.69%, while medical devices and traditional Chinese medicine saw declines [1][32]. ANGPTL3 Developments - A collaboration between Argo Biopharma and Novartis was announced, focusing on RNA drugs for cardiovascular diseases, with a total potential payment of $5.2 billion, including a $160 million upfront payment [2][11]. - ANGPTL3's mechanism allows for significant reductions in LDL-C levels in patients with HoFH, outperforming traditional treatments like PCSK9 inhibitors [3][31]. Company Earnings Forecasts and Ratings - Key companies in the sector, such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital, have been rated as "Outperform" with projected net profits for 2024 ranging from 1.4 billion to 116.7 billion yuan [4][41]. - The report provides detailed earnings forecasts for various companies, indicating a positive outlook for the sector as a whole [4][41]. Valuation Metrics - The TTM price-to-earnings ratio for the pharmaceutical and biotechnology sector stands at 40.75x, significantly higher than the overall A-share market's 19.80x [37][38]. - Sub-sectors such as chemical pharmaceuticals and biological products have even higher valuations, indicating strong investor interest and growth potential [37][38]. Recommended Stocks - The report recommends several companies, including Mindray Medical for its strong market position and international expansion, WuXi AppTec for its comprehensive drug development services, and Aier Eye Hospital for its leading position in the eye care sector [41][42].

Group 1 - The core viewpoint of the news highlights the strong performance of certain biotech stocks in the Hong Kong market, particularly the significant rise of药捷安康-B by over 25% and the moderate increases of 映恩生物-B and MIRXES-B by over 6% and 5% respectively, while 三生制药, 君实生物, and 康方生物 experienced notable declines [1] - 百济神州 presented promising II phase clinical data for its drug combination therapy at the WCLC conference, achieving a 100% overall response rate (ORR) with manageable safety, and has initiated a phase III trial in China [1] - 方正证券 suggests that the long-term bullish trend for innovative drugs may not be over, as the commercialization value of innovative drug assets driven by China's engineering talent has yet to be fully realized, with low valuations in the Hong Kong innovative drug sector and a high certainty of business development (BD) transactions [1] - 万联证券 forecasts a recovery in the Hong Kong innovative drug industry by mid-2025 after four years of adjustment, driven by BD transactions and positive data from the ASCO conference, with significant revenue and profit growth attributed to accelerated international expansion and commercialization [1] Group 2 - The Hong Kong Stock Connect Innovative Drug ETF (520880) passively tracks the Hang Seng Stock Connect Innovative Drug Select Index (HSSCPB), with its top ten weighted stocks including 中国生物制药, 百济神州, and 石药集团 [2] - The latest data shows the top ten stocks in the index, with 中国生物制药 holding a weight of 10.24%, 百济神州 at 10.11%, and 石药集团 at 10.10%, indicating a diversified portfolio within the innovative drug sector [3]